Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis Announces Iptacopan Met Primary Endpoint in Rare Kidney Disease IgA Nephropathy

americanpharmaceuticalreviewJune 09, 2021

Tag: Novartis , iptacopan , IgAN

PharmaSources Customer Service